GSK3B and neoplasm: In conclusion, PRL-3 exhibited the characteristics of a tumor suppressor in NSCLC, and the phosphatase's inhibitory effect on lung cancer progression might occur through the down-regulation of Slug expression via the AKT-GSK3β pathway, further leading to increases in E-cadherin.